
Grupo para el estudio de las enfermedades infecciosas
Lineas de Investigación
01. Infección VIH.
02. Infección endovascular.
03. Gérmenes multirresistentes.
04. Identificación de MNT por MALDITOF
Miembros del grupo
- Todos
- IR
- Co-IR
- Investigador
- Tecnico Laboratorio
- Otro

Proyectos de Investigación
EMG20-001 Ayudas para el fortalecimiento de grupos emergentes
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludPLAN PROPIO_AREA4 Optimización del diagnóstico de la infección por C. difficile y detección de marcadores microbiológicos de gravedad y mala evolución. María Dolores Rojo.
FIMABISEstudios Clínicos
CDC-Ensayo clínico de Sarilumab en adultos hospitalizados con COVID-19 que presentan síndrome de liberación de citoquinas.
FIBICO. FUNDACION PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBACDC-Ensayo clínico fase I/II multicéntrico, aleatorizado y controlado para evaluar la eficacia del tratamiento con plasma hiperinmune obtenido de donantes convalecientes de la infección por COVID-19.
FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUDEstudio Salutem: uso de hidroxicloroquina en profilaxis pre-exposición a la COVID-19 en trabajadores sanitarios.
AGENCIA PUBLICA EMPRESARIAL SANITARIA COSTA DEL SOLCDC-Estudio Prevención y tratamiento con Calcifediol del síndrome respiratorio agudo (SARS) inducido por Coronavirus COVID-19.
FIBICO. FUNDACION PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBAEnsayo clínico abierto y multicéntrico para evaluar la efectividad y seguridad de tocilizumab intravenoso en el tratamiento de pacientes con neumonía por COVID-19: estudio BREATH-19.
FUNDACION SEIMC-GESIDATemocilina vs Meropenem para el Tratamiento de la Bacteriemia por Enterobacteriales Resistentes a Cefalosporinas de Tercera Generación: Ensayo Aleatorizado y Pragmático..
FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACIÓN EN SALUD DE SEVILLA FISEVIEstudio de Fase 3 Aleatorizado para Evaluar la Seguridad y la Actividad Antiviral de Remdesivir (GS-5734™) en Participantes con infección moderada por el COVID-19 en comparación con el tratamiento de referencia.
GILEAD SCIENCES, INCEstudio de Fase 3 Aleatorizado para Evaluar la Seguridad y la Actividad Antiviral de Remdesivir (GS-5734™) en Participantes con infección grave por el COVID-19..
GILEAD SCIENCES, INC201585. Estudio Fase III aleatorizado, multicéntrico, abierto, de grupos paralelos, de no inferioridad, para evaluar la eficacia, seguridad y tolerabilidad del cambio de una terapiaantirretroviral basada en INI, ITINN o IP a una pauta de tratamiento intramuscular
LABORATORIOS VIIV HEALTHCARE S.L.205543. Estudio de fase III, aleatorizado, doble ciego, multicéntrico, con grupos paralelos, de ausencia de inferioridad, para evaluar la eficacia, seguridad y tolerabilidad de dolutegravir más lamivudina en comparación con dolutegravir más tenofovir/emtricitabin
LABORATORIOS VIIV HEALTHCARE S.L.GS-US-292-1823. Estudio de fase 3b, aleatorizado y abierto para evaluar la seguridad y la eficacia del cambio de una pauta de abacavir/lamivudina (ABC/3TC) más un tercer antirretroviral a la combinación de dosis fijas (CDF) elvitegravir/cobicistat/emtricitabina/tenofovir
GILEAD SCIENCES, INCGS-US-292-1824. Estudio piloto de fase 3b abierto para evaluar el cambio a la combinación de dosis fijas (CDF) elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida (E/C/F/TAF) en sujetos adultos infectados por el VIH-1 con supresión virológica que tienen la mutaci
GILEAD SCIENCES, INCSIMPLIFY. Ensayo clínico aleatorizado, multicéntrico, abierto, controlado, en fase III, para demostrar la no inferioridad del tratamiento antibiótico dirigido de espectro reducido frente al tratamiento de amplio espectro con un betalactámico antipseudomónico en el
FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACIÓN EN SALUD DE SEVILLA. FISEVI FISEVIFOREST. Ensayo clínico aleatorizado, multicéntrico, abierto, controlado, en fase III, para evaluar la eficacia de fosfomicina vs meropenem en el tratamiento dirigido de la infección urinaria bacteriémica por Escherichia coli productor de betalactamasas de espectr
FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACIÓN EN SALUD DE SEVILLA. FISEVI FISEVIPublicaciones científicas
- Todo
- D1
- Q1
- Q2
- Otro
Blood culture-negative infective endocarditis: a worse outcome? Results from a large multicentre retrospective Spanish cohort study
Suardi LR, de Alarcón A, García MV, Ciezar AP, Hidalgo Tenorio C, et al. Infectious diseases (London, England) 2021 Oct;53(10):755-763
Clinical Factors Associated with Reinfection versus Relapse in Infective Endocarditis: Prospective Cohort Study
Calderón-Parra J, Kestler M, Ramos-Martínez A, Bouza E, Valerio M, et al. Journal of clinical medicine 2021 Feb 13;10(4):
Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international study
Gudiol C, Durà-Miralles X, Aguilar-Company J, Hernández-Jiménez P, Martínez-Cutillas M, et al. The Journal of infection 2021 Sep;83(3):306-313
Do specific antimicrobial stewardship interventions have an impact on carbapenem resistance in Gram-negative bacilli? A multicentre quasi-experimental ecological study: time-trend analysis and characterization of carbapenemases
Álvarez-Marín R, López-Cerero L, Guerrero-Sánchez F, Palop-Borras B, Rojo-Martín MD, et al. The Journal of antimicrobial chemotherapy 2021 Jun 18;76(7):1928-1936
Epidemiologic changes in bloodstream infections in Andalucia (Spain) during the last decade
Martínez Pérez-Crespo PM, López-Cortés LE, Retamar-Gentil P, García JFL, Vinuesa García D, et al. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2021 Feb;27(2):283.e9-283.e16
Infections after spine instrumentation: effectiveness of short antibiotic treatment in a large multicentre cohort
Benavent E, Rodríguez-Pardo D, Ulldemolins M, Sobrino-Diaz B, Bustinduy MJ, et al. The Journal of antimicrobial chemotherapy 2021 Mar 12;76(4):1085-1093
Linezolid for infective endocarditis A structured approach based on a national database experience
Muñoz P, De la Villa S, Martínez-Sellés M, Goenaga MA, Reviejo-Jaka K, et al. Medicine 2021 Dec 23;100(51):e27597
Mural Endocarditis: The GAMES Registry Series and Review of the Literature
Gutiérrez-Villanueva A, Muñoz P, Delgado-Montero A, Olmedo-Samperio M, de Alarcón A, et al. Infectious diseases and therapy 2021 Dec;10(4):2749-2764
Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder
Galván ST, Flores-López M, Romero-Sanchiz P, Requena-Ocaña N, Porras-Perales O, et al. Scientific reports 2021 Jul 1;11(1):13629
Plasma Concentrations of Lysophosphatidic Acid and Autotaxin in Abstinent Patients with Alcohol Use Disorder and Comorbid Liver Disease
Flores-López M, García-Marchena N, Pavon FJ, Lara E, Porras-Perales O, et al. Biomedicines 2021 Sep 13;9(9):
Revisiting the epidemiology of bloodstream infections and healthcare-associated episodes: results from a multicentre prospective cohort in Spain (PRO-BAC Study)
Pérez-Crespo PMM, Lanz-García JF, Bravo-Ferrer J, Cantón-Bulnes ML, Sousa Domínguez A, et al. International journal of antimicrobial agents 2021 Jul;58(1):106352
Skin lesions in children during the first wave of the SARS-CoV-2 pandemic
Carazo Gallego B, Martín Pedraz L, Galindo Zavala R, Rivera Cuello M, Mediavilla Gradolph C, et al. Medicina clinica 2021 Jul 9;157(1):33-37
Skin manifestations during the COVID-19 pandemic in the pediatric emergency department
Oliva Rodríguez-Pastor S, Martín Pedraz L, Carazo Gallego B, Galindo Zavala R, Lozano Sánchez G, et al. Pediatrics international : official journal of the Japan Pediatric Society 2021 Sep;63(9):1033-1037
The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant
López MG, Chiner-Oms Á, García de Viedma D, Ruiz-Rodriguez P, Bracho MA, et al. Nature genetics 2021 Oct;53(10):1405-1414
Update in Diagnostics of Toscana Virus Infection in a Hyperendemic Region (Southern Spain)
Sanbonmatsu-Gámez S, Pedrosa-Corral I, Navarro-Marí JM, Pérez-Ruiz M Viruses 2021 Jul 23;13(8):
Catheter-related bloodstream infections: predictive factors for Gram-negative bacteria aetiology and 30 day mortality in a multicentre prospective cohort
Calò F, Retamar P, Martínez Pérez-Crespo PM, Lanz-García J, Sousa A, et al. The Journal of antimicrobial chemotherapy 2020 Oct 1;75(10):3056-3061
Clinical and prognostic differences between methicillin-resistant and methicillin-susceptible Staphylococcus aureus infective endocarditis
Hidalgo-Tenorio C, Gálvez J, Martínez-Marcos FJ, Plata-Ciezar A, De La Torre-Lima J, et al. BMC infectious diseases 2020 Feb 21;20(1):160
Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa
Gudiol C, Albasanz-Puig A, Laporte-Amargós J, Pallarès N, Mussetti A, et al. Antimicrobial agents and chemotherapy 2020 Mar 24;64(4):
Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial
León López R, Fernández SC, Limia Pérez L, Romero Palacios A, Fernández-Roldán MC, et al. BMJ open 2020 Nov 14;10(11):e039951
Four weeks versus six weeks of ampicillin plus ceftriaxone in Enterococcus faecalis native valve endocarditis: A prospective cohort study
Ramos-Martínez A, Pericàs JM, Fernández-Cruz A, Muñoz P, Valerio M, et al. PloS one 2020;15(8):e0237011
Impact of HIV on the survival of hepatocellular carcinoma in hepatitis C virus-infected patients
Merchante N, Rodríguez-Fernández M, Figueruela B, Rodríguez-Arrondo F, Revollo B, et al. AIDS (London, England) 2020 Aug 1;34(10):1497-1507
Outcomes of the PIRASOA programme, an antimicrobial stewardship programme implemented in hospitals of the Public Health System of Andalusia, Spain: an ecologic study of time-trend analysis
Rodríguez-Baño J, Pérez-Moreno MA, Peñalva G, Garnacho-Montero J, Pinto C, et al. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020 Mar;26(3):358-365
Quasiexperimental intervention study protocol to optimise the use of new antibiotics in Spain: the NEW_SAFE project
Palacios-Baena ZR, Valiente de Santis L, Maldonado N, Rosso-Fernández CM, Borreguero I, et al. BMJ open 2020 Jul 31;10(7):e035460
What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: a modeling analysis
Skaathun B, Borquez A, Rivero-Juarez A, Mehta SR, Tellez F, et al. BMC infectious diseases 2020 Aug 8;20(1):588
A prospective survey of Aspergillus spp. in respiratory tract samples: Species identification and susceptibility patterns
Castro C, Galán-Sanchez F, Linares MJ, Tejero R, Ruiz M, et al. Medical mycology 2019 Jun 1;57(4):412-420
DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
Hidalgo-Tenorio C, Vinuesa D, Plata A, Martin Dávila P, Iftimie S, et al. Annals of clinical microbiology and antimicrobials 2019 Oct 19;18(1):30
Evaluation of a rapid assay for detection of PBP2a Staphylococcus aureus
Sáinz-Rodríguez R, de Toro-Peinado I, Valverde-Troya M, Bermúdez Ruíz MP, Palop-Borrás B Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 2019 Aug;32(4):370-374
Evaluation of hepatitis C viral RNA persistence in HIV-infected patients with long-term sustained virological response by droplet digital PCR
Frías M, Rivero-Juárez A, Téllez F, Palacios R, Jiménez-Arranz Á, et al. Scientific reports 2019 Aug 29;9(1):12507
Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study
Albasanz-Puig A, Gudiol C, Parody R, Tebe C, Akova M, et al. BMJ open 2019 May 24;9(5):e025744
Left-sided infective endocarditis caused by Streptococcus agalactiae: rare and serious
Ivanova-Georgieva R, Ruiz-Morales J, García-Cabrera E, García-López MV, Gálvez-Acebal J, et al. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2019 Feb;38(2):265-275
Losses to follow-up of HIV-infected people in the Spanish VACH cohort over the period between 2013 and 2014: The importance of sociodemographic factors
Teira R, Espinosa N, Gutiérrez MM, Montero M, Martínez E, et al. Enfermedades infecciosas y microbiologia clinica (English ed.) 2019 Jun – Jul;37(6):361-366
Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients
Merchante N, Figueruela B, Rodríguez-Fernández M, Rodríguez-Arrondo F, Revollo B, et al. AIDS (London, England) 2019 Feb 1;33(2):269-278
Outpatient Parenteral Antibiotic Treatment for Infective Endocarditis: A Prospective Cohort Study From the GAMES Cohort
Pericà S JM, Llopis J, González-Ramallo V, Goenaga MÁ, Muñoz P, et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019 Oct 30;69(10):1690-1700
OXA-48-Like-Producing Klebsiella pneumoniae in Southern Spain in 2014-2015
Machuca J, López-Cerero L, Fernández-Cuenca F, Mora-Navas L, Mediavilla-Gradolph C, et al. Antimicrobial agents and chemotherapy 2019 Jan;63(1):
Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients
Rivero-Juarez A, Tellez F, Castaño-Carracedo M, Merino D, Espinosa N, et al. HIV medicine 2019 Jul;20(6):359-367
Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
Manuel Sousa J, Vergara M, Pulido F, Sánchez Antolín G, Hijona L, et al. PloS one 2019;14(11):e0225061
Response to Hepatitis A Virus Vaccine in HIV-Infected Patients Within a Retrospective, Multicentric Cohort: Facing Hepatitis A Outbreaks in the Clinical Practice
Neukam K, Delgado Fernández M, Hernández Quero J, Rivero-Juárez A, Llaves-Flores S, et al. Journal of acquired immune deficiency syndromes (1999) 2019 May 1;81(1):e1-e5
The Different Microbial Etiology of Prosthetic Joint Infections according to Route of Acquisition and Time after Prosthesis Implantation, Including the Role of Multidrug-Resistant Organisms
Benito N, Mur I, Ribera A, Soriano A, Rodríguez-Pardo D, et al. Journal of clinical medicine 2019 May 13;8(5):
A pragmatic approach for mortality prediction after surgery in infective endocarditis: optimizing and refining EuroSCORE
Fernández-Hidalgo N, Ferreria-González I, Marsal JR, Ribera A, Aznar ML, et al. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2018 Oct;24(10):1102.e7-1102.e15
Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy
Mensa J, Barberán J, Soriano A, Llinares P, Marco F, et al. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 2018 Feb;31(1):78-100
Appropriateness of antimicrobial prescriptions in the emergency department of a tertiary hospital
Yunquera-Romero L, Márquez-Gómez I, Henares-López A, Morales-Lara MJ, Gallego Fernández C, et al. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 2018 Jun;31(3):209-216
Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real life
Real LM, Macías J, Pérez AB, Merino D, Granados R, et al. Scientific reports 2018 Oct 8;8(1):14905
Dalbavancin in the treatment of different gram-positive infections: a real-life experience
Bouza E, Valerio M, Soriano A, Morata L, Carus EG, et al. International journal of antimicrobial agents 2018 Apr;51(4):571-577
Emergence as an outbreak of the HIV-1 CRF19_cpx variant in treatment-naive patients in southern Spain
González-Domenech CM, Viciana I, Delaye L, Mayorga ML, Palacios R, et al. PloS one 2018;13(1):e0190544
Factors associated with bronchiectasis in patients with uncontrolled asthma; the NOPES score: a study in 398 patients
Padilla-Galo A, Olveira C, Fernández de Rota-Garcia L, Marco-Galve I, Plata AJ, et al. Respiratory research 2018 Mar 16;19(1):43
Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients
Merchante N, Rodríguez-Arrondo F, Revollo B, Merino E, Ibarra S, et al. AIDS (London, England) 2018 Jul 17;32(11):1423-1430
High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial
Pasquau J, Hidalgo-Tenorio C, Montes ML, Romero-Palacios A, Vergas J, et al. PloS one 2018;13(4):e0195068
HIV in Spain 2017: policies for a new management of chronicity beyond virological control
Del Amo J, Campbell C, Navarro G, Segura F, Suárez I, et al. Revista espanola de salud publica 2018 Sep 6;92():
How to: identify non-tuberculous Mycobacterium species using MALDI-TOF mass spectrometry
Alcaide F, Amlerová J, Bou G, Ceyssens PJ, Coll P, et al. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2018 Jun;24(6):599-603
Infective Endocarditis in Patients With Bicuspid Aortic Valve or Mitral Valve Prolapse
Zegri-Reiriz I, de Alarcón A, Muñoz P, Martínez Sellés M, González-Ramallo V, et al. Journal of the American College of Cardiology 2018 Jun 19;71(24):2731-2740
Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study
Ocampo A, Domingo P, Fernández P, Diz J, Barberá JR, et al. The Journal of antimicrobial chemotherapy 2018 Aug 1;73(8):2171-2176
Serotypes and genotypes of S. pneumoniae isolates from adult invasive disease in Spain: A 5-year prospective surveillance after pediatric PCV13 licensure. The ODIN study
Fenoll A, Ardanuy C, Liñares J, Cercenado E, Marco F, et al. Vaccine 2018 Dec 18;36(52):7993-8000
Evaluation of an immunochromatographic test for the detection of OXA-48 carbapenemase
Mediavilla-Gradolph C, Sáinz-Rodriguez R, Valverde-Troya M, de Toro-Peinado I, Bermudez-Ruíz MP, et al. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 2017 Feb;30(1):45-49
Factors associated with severe sepsis or septic shock in complicated pyelonephritis
Ruiz-Mesa JD, Marquez-Gomez I, Sena G, Buonaiuto VA, Mora-Ordoñez J, et al. Medicine 2017 Oct;96(43):e8371
Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals
Arboledas JCA, Guerrero IP, Rodríguez MJB, Martos ET, Pérez AB, et al. Diagnostic microbiology and infectious disease 2017 Sep;89(1):29-34
Lessons learned with molecular methods targeting the BCSP-31 membrane protein for diagnosis of human brucellosis
Sanjuan-Jimenez R, Colmenero JD, Morata P Clinica chimica acta; international journal of clinical chemistry 2017 Jun;469():1-9
Prognostic factors of infective endocarditis in patients on hemodialysis: A case series from a National Multicenter Registry
Ramos-Martínez A, Roque F, Fariñas MC, Muñoz P, Verde E, et al. International journal of cardiology 2017 Aug 15;241():295-301
Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients
Merchante N, Ibarra S, Revollo B, Rodríguez-Arrondo F, Merino E, et al. AIDS (London, England) 2017 Jan 2;31(1):89-95
Very low level viraemia and risk of virological failure in treated HIV-1-infected patients
Teira R, Vidal F, Muñoz-Sánchez P, Geijo P, Viciana P, et al. HIV medicine 2017 Mar;18(3):196-203
Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection
Pineda JA, Morano-Amado LE, Granados R, Macías J, Téllez F, et al. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2017 Jun;23(6):409.e5-409.e8
Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study
Laguno M, Von Wichmann MA, Van den Eynde E, Navarro J, Cifuentes C, et al. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2016 Dec;53():46-51
Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study
Neukam K, Espinosa N, Collado A, Delgado-Fernández M, Jiménez-Aguilar P, et al. PloS one 2016;11(5):e0155842
No evidence of firstly acquired acute hepatitis C virus infection outbreak among HIV-infected patients from Southern Spain: a multicentric retrospective study from 2000-2014
Neukam K, Viciana P, Ojeda-Burgos G, Delgado-Fernández M, Ríos MJ, et al. BMC infectious diseases 2016 Sep 15;16():489
Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy
Neukam K, Munteanu DI, Rivero-Juárez A, Lutz T, Fehr J, et al. PloS one 2015;10(4):e0125080
Comparative Study of a Real-Time PCR Assay Targeting senX3-regX3 versus Other Molecular Strategies Commonly Used in the Diagnosis of Tuberculosis
Sanjuan-Jimenez R, Toro-Peinado I, Bermudez P, Colmenero JD, Morata P PloS one 2015;10(11):e0143025
Left-sided infective endocarditis in patients with liver cirrhosis.
Ruiz-Morales J, Ivanova-Georgieva R, Fernández-Hidalgo N, García-Cabrera E, Miró JM, et al. The Journal of infection 2015 Dec;71(6):627-41
Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection
Macías J, López-Cortés LF, Téllez F, Recio E, Ojeda-Burgos G, et al. PloS one 2015;10(12):e0143492
Enlaces
Calle Severo Ochoa, 35
Parque Tecnol?gico de Andaluc?a (PTA) Campanillas,
M?laga 29590
(+34) 951 440 260
Fax: (+34) 951 440 263